About Regencell Bioscience Holdings Limited - Ordinary Shares (RGC)
Regencell Bioscience Holdings Ltd is a biotechnology company focused on developing innovative therapies for neurological disorders. The company is actively engaged in the research and commercialization of novel treatments aimed at addressing conditions such as attention deficit hyperactivity disorder (ADHD) and other cognitive impairments. Through its cutting-edge approaches and commitment to scientific advancement, Regencell strives to enhance the quality of life for individuals affected by these challenges, with a strong emphasis on evidence-based solutions and therapeutic efficacy. Read More
LOS ANGELES, April 28, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Regencell Bioscience Holdings Limited (“Regencell” or “the Company”) (NASDAQ: RGC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Regencell (RGC) To Contact Him Directly To Discuss Their Options
Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers and acquirers of Regencell Bioscience Holdings Limited (NASDAQ: RGC) securities between October 28, 2024 and October 31, 2025, inclusive (the “Class Period”). Regencell is a purported early-stage bioscience company.
Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Regencell Bioscience Holdings Limited (NASDAQ: RGC) securities between October 28, 2024 and October 31, 2025. Regencell is a purported early-stage bioscience company focused on the research, development, and commercialization of traditional Chinese medicine (“TCM”) for the treatment of attention-deficit/hyperactivity disorder (“ADHD”) and autism spectrum disorder (“ASD”).
NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Regencell Bioscience Holdings Limited (NASDAQ:RGC) and Camping World Holdings, Inc. (NYSE:CWH). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.
NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Regencell Bioscience Holdings Limited (NASDAQ:RGC) and Camping World Holdings, Inc. (NYSE:CWH). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.
As the final bells rang on the 2025 trading year, investors in Regencell Bioscience (NASDAQ: RGC) were met with a sobering reality check. The Hong Kong-based biotech firm, which has enjoyed a meteoric and often volatile rise over the past twelve months, saw its stock slide 8.3% on December
NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Regencell Bioscience Holdings Limited (NASDAQ:RGC) and Camping World Holdings, Inc. (NYSE:CWH). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.
